Keywords

• DesMethyl Erlotinib (CP-473420) HCl,
• 183320-51-6
• 99% OSI-420

Quick Details

• ProName: OSI-420
• CasNo: 183320-51-6
• Molecular Formula: C21H21N3O4.HCl
• Application: 183320-51-6
• DeliveryTime: in stock
• ProductionCapacity: 100g Metric Ton/Day
• Purity: 99%
• LimitNum: 1 Gram

Superiority

In stock ,If you need HNMR\HPLC,please contact us!

Details

OSI-420 is the major metabolite of Erlotinib in human plasma. Erlotinib disappearance from plasma after a short IV infusion is biexponential with a mean terminal half-life of 5.2 h and a mean clearance of 128 ml/min per m(2). OSI-420 exposure (AUC) in plasma is 30% (range 12-59%) of erlotinib, and OSI-420 clearance is more than 5-fold higher than erlotinib. Erlotinib and OSI-420 are equipotent, and the combined concentrations of erlotinib + OSI-420 achieved in the CSF exceeded the IC50 (7.9 ng/ml or 20 nM) for the EGFR tyrosine kinase inhibition in intact tumor cells. Erlotinib potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib (1 μM) induces apoptosis in DiFi humancolon cancer cells . Erlotinib growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM .  Erlotinib(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells .